Laboratory Changes During Dupilumab Treatment for Atopic Dermatitis

Laboratory Changes During Dupilumab Treatment for Atopic Dermatitis

Introduction: Dupilumab is an IL-4/IL-13 inhibitor monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD) with remarkable safety and efficacy profiles. However, former studies have reported an increase in serum eosinophils during treatment, with undetermined clin...

Full description

Saved in:
Bibliographic Details
Main Authors: D. Flor, C. Montero-Vilchez, T. Montero-Vilchez, S. Arias-Santiago, M. Gonçalo
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Actas Dermo-Sifiliográficas
Subjects:
Dupilumab
Dermatitis atópica
Eosinófilos
IgE
LDH
Online Access:http://www.sciencedirect.com/science/article/pii/S0001731024010597
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items